Trial Results
A plain-English summary of what published Huntington's disease clinical trial results actually show. It is based only on outcomes reported in the trial registries Fenix tracks — not on news, announcements or opinion.
Results announced — not yet independently verified
These results were announced by the trial sponsor, but have not yet been independently verified by Fenix through a peer-reviewed publication or trial-registry results record. They are therefore not included in the verified results summary below.
AMT-130 (uniQure)
Sponsor announcementNot independently verifiedSponsor-reported topline results
Announced 24 September 2025
uniQure announced topline results from its ongoing gene therapy programme for Huntington's disease, reporting that people who received the higher dose of AMT-130 declined more slowly than an external comparison group after three years. The company also reported that the therapy was generally well tolerated. These figures come from the company itself and have not yet been published in a peer-reviewed journal or posted to a trial registry, so Fenix has not been able to check them independently.
Read the uniQure company announcement
Other studies
Several completed trials show that some drugs reduced involuntary movements (chorea). Other large trials did not show improvement in day‑to‑day function, and some studies reported only laboratory or brain‑scan changes. A change in a laboratory measure or brain protein does not by itself prove that a treatment helps symptoms or slows Huntington's disease.
Key results
- Positive findingTreatment for symptoms
In KINECT‑HD, valbenazine reduced involuntary movements (the Unified Huntington's Disease Rating Scale Total Maximal Chorea score). This was the study's primary measure and the difference was statistically significant.
Main measure of the trial
Reported figures: p < 0.0001; change -4.60 vs -1.44 points.
- Positive findingTreatment for symptoms
In First‑HD, deutetrabenazine reduced involuntary movements (Total Maximal Chorea score). This was the trial's primary measure and the result was statistically significant.
Main measure of the trial
Reported figures: p < 0.0001; change -4.42 vs -1.93 points.
- Positive findingTreatment for symptoms
In a Phase 2b study, SOM3355 reduced involuntary movements (Total Maximal Chorea) in participants not taking neuroleptic drugs; the primary measure was statistically significant over 10 weeks.
Main measure of the trial
Reported figures: p = 0.045; reported changes ranged about -2.19 to -3.46 points (mITT, N=122).
- InconclusiveLaboratory measure only
PTC518 produced a statistically significant lowering of a blood huntingtin protein measure (geometric mean total huntingtin, tHTT) at Month 3. This was the trial's primary (biomarker) measure.
Laboratory measure, not symptoms
Reported figures: p < 0.0001; percent changes at Month 3 reported as about -1.40%, -17.36%, and -28.67% in different dose groups.
- Negative findingTreatment for symptoms
PROOF‑HD (pridopidine) did not meet its primary measure of day‑to‑day function (Total Functional Capacity); the primary outcome was not statistically significant.
Additional measure only — main measure not confirmed
Reported figures: p = 0.1670; change -1.18 vs -0.95 points (mITT, to Week 65).
What a "statistically significant" result means
A statistically significant result means the data are unlikely to be due to chance, but it does not automatically mean a treatment improves everyday life or slows Huntington's disease. Changes in laboratory tests or brain proteins are not the same as symptom or function improvement.
What the evidence cannot yet tell us
- Many registry entries report only numbers without p‑values or do not provide enough detail to judge whether changes matter to daily life.
- Several findings are laboratory or imaging changes; these do not prove that a treatment improves symptoms or slows disease.
- Long‑term benefits and safety for many treatments are not clear from the posted results.
View the clinical trial results and sources used to generate this summary.
Based on 111 evidence records · Updated 27 Sep 2026
Last updated: 27 September 2026 at 03:33
This summary is generated from publicly available clinical trial results and is intended to help explain trial results in plain English. It is not medical advice.